FDA Inspection 1265595 — Zhejiang Guobang Pharmaceutical Co., Ltd
The FDA completed an inspection of Zhejiang Guobang Pharmaceutical Co., Ltd on Mar 3, 2025 in Shaoxing. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 3, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Shaoxing (China)